Jean-Marie Cuillerot

Jean-Marie Cuillerot, M.D., is Chief Medical Officer at Acrivon Therapeutics, Inc. Jean-Marie was previously the Chief Medical Officer at Dragonfly Therapeutics where he established and led a clinical team advancing multiple potential first-in-class assets. Prior to Dragonfly, Jean-Marie was the chief medical officer of Agenus, where he led development activities for five investigational therapies. At EMD Serono, an affiliate of Merck Serono, Jean-Marie served as the global head of clinical development in immuno-oncology (IO) and as the vice president of clinical immunotherapy/IO. He oversaw the company’s IO portfolio which included two checkpoint inhibitors and two immuno-cytokines. Notably, Jean-Marie led the clinical development of avelumab, the first drug approved to treat Merkel cell carcinoma and second-line bladder cancer, from pre-IND though global submissions in record time, an achievement that earned him the Merck CEO Award. From 2007 to 2012, he was at Bristol- Myers Squibb, where he was medical lead for the life cycle management of ipilimumab, an anti-CTLA-4 antibody and the world’s first immune checkpoint therapy for cancer, where he designed and led Phase 2 and Phase 3 studies across multiple indications and supported regulatory filings in the United States and Europe. Earlier in his career, Jean-Marie also served in clinical development at Novartis, as a clinical research physician at the Centre d’Immunologie Pierre Fabre, and as an assistant professor at the Hôpitaux Universitaires de Strasbourg. Jean-Marie received a B.S. in biochemistry, an M.Sc. in cellular and molecular biology and an M.D. at the University Louis Pasteur (Strasbourg, France).